[go: up one dir, main page]

WO2003074039A1 - Compositions permettant de prevenir l'hypertension - Google Patents

Compositions permettant de prevenir l'hypertension Download PDF

Info

Publication number
WO2003074039A1
WO2003074039A1 PCT/JP2002/001967 JP0201967W WO03074039A1 WO 2003074039 A1 WO2003074039 A1 WO 2003074039A1 JP 0201967 W JP0201967 W JP 0201967W WO 03074039 A1 WO03074039 A1 WO 03074039A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetic acid
blood pressure
test
sat
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001967
Other languages
English (en)
Japanese (ja)
Inventor
Kenji Tayama
Shino Kondou
Sumio Akita
Yoshinori Tsukamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mizkan Group Corp
Original Assignee
Mizkan Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001298211A priority Critical patent/JP2002255801A/ja
Priority claimed from JP2001298211A external-priority patent/JP2002255801A/ja
Application filed by Mizkan Group Corp filed Critical Mizkan Group Corp
Priority to PCT/JP2002/001967 priority patent/WO2003074039A1/fr
Priority to US10/506,325 priority patent/US20050256195A1/en
Priority to CA002477900A priority patent/CA2477900A1/fr
Priority to KR10-2004-7013025A priority patent/KR20040094717A/ko
Publication of WO2003074039A1 publication Critical patent/WO2003074039A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • composition for preventing hypertension Composition for preventing hypertension
  • the present invention relates to a composition for preventing hypertension, and more particularly, to a food or pharmaceutical composition which has the effect of suppressing blood pressure increase by long-term oral ingestion and can be used for preventing hypertension.
  • Hypertension is a symptom of a large number of patients and reserves in lifestyle-related diseases. According to the National Nutrition Survey in 1999 (Current Status of National Nutrition, Health and Nutrition Information Research Group, edited by Daiichi Shuppan, p. According to the blood pressure values, 25.3% are male and 20.6% are female, and 19.8% are male and 14.5% are females. Were present in the proportions. From the moment of this investigation, the situation was extremely problematic, meaning that there were more than 1,000,000 hypertension reserves in Japan. Although the cause of hypertension has not been elucidated, a predisposition (genetic) and environment (lifestyle) are involved and are thought to be due to their interaction.
  • An object of the present invention is to find a substance which suppresses a rise in blood pressure due to long-term oral ingestion, has almost no side effects, is extremely inexpensive, and is easy to obtain. To provide the composition.
  • SHR rats which are model animals of essential hypertension
  • various purified substances are added to a standard diet to a final concentration of 0.3% and mixed.
  • the sample was administered.
  • the effect of the sample administration was evaluated by using one SHR rat per sample, rearing the sample for 8 weeks, and comparing the blood pressure value with the average value of the control group (6 animals) to which no purified substance was added.
  • a method is used in which a fixed amount of a certain amount of a pure reagent aqueous solution is forcibly administered orally every day to the body weight of an animal such as a rat.
  • acetic acid taken orally is transferred to the portal vein in a form that is more than 125 times diluted, and the metabolism of acetic acid in the body is rapid.
  • the blood acetic acid concentration rapidly decreased and that the venous acetic acid concentration hardly changed.
  • acetic acid was supplied from the drip, which increased to 0.5 to 2.5 mg / d1 (average 1.5 mgZdl), but the blood pressure was not significant, but the test drug was administered. It was slightly higher than just before the start.
  • the present inventors independently measured a large number of acetic acid concentrations in human blood on an empty stomach, and found that the highest concentration was 0.6 mgZdl (0.1 lmM) and the lowest concentration was 0 (undetected). This was consistent with literature results.
  • vinegar can be given as a seasoning.
  • black vinegar a type of vinegar, reduced blood pressure in people with high blood pressure.
  • the active ingredient is searched for in black vinegar, but has not been identified.
  • ACE angiotensin converting enzyme
  • ginseng vinegar suppressed the increase in blood pressure in stroke-prone spontaneously hypertensive rats (SHRSP) (Pharmacology and Treatment, Vol. 26, p. 23, pp. 1998).
  • SHRSP stroke-prone spontaneously hypertensive rats
  • vinegar has a blood pressure lowering effect
  • vinegar contains only about 4 to 5% of acetic acid.
  • the functional components generated by its processing ".
  • Acetic acid itself has a sour taste, and it is practically impossible to take it at a high concentration. Conversely, even at low concentrations, large intakes are difficult. Therefore, it is necessary to consume acetic acid in a certain moderate concentration range. To alleviate sourness, it is possible to neutralize with alcohol and add a large amount of other flavor components, but it may increase unpleasant taste, over-consumption of minerals, and nutritional bias. Challenges arise and are not easy. Therefore, in the present invention, the intake concentration was also examined, and 0.30 g to 30 g of acetic acid molecules were contained per 100 g of the composition. It was determined that it was preferable to
  • the results are converted to humans.Adults weighing 60 kg on average consume 0.5 g to 5 g of acetic acid per day, thereby delaying hypertension, that is, the effect of preventing hypertension. He revealed that there was something.
  • the act of continuously ingesting the composition of the present invention is based on the results of experiments, as shown in the table below, for those who have the possibility of having high blood pressure in the future, or for those whose blood pressure value is in the boundary region (maximum blood pressure is 140 to 180 mmHg). It contributes to the prevention of hypertension for humans.
  • the present invention has been completed based on the above findings. That is, the present invention includes the following inventions.
  • a food or pharmaceutical composition for preventing hypertension which is a composition for suppressing an increase in blood pressure by long-term oral ingestion, comprising at least one selected from acetic acid, acetate ion and acetate.
  • composition according to (1) wherein the composition contains at least one selected from acetic acid, acetate ion, and acetate salt in a total amount of 0.36 g to 30 g (in terms of acetic acid) per 1000 g of the composition.
  • Acetic acid used in the present invention is not particularly limited in its production method, and may be one produced by a synthetic method or one produced by a fermentation method.
  • acetic acid produced by fermentation that is, vinegar (brewed vinegar).
  • Brown rice vinegar, which is hard to feel, and apple vinegar, which has a refreshing aroma, are more preferable.
  • acetic acid can be supplied while reducing acidity.
  • various acetates such as sodium acetate can be used.
  • the acetic acid concentration in this specification refers to the acetic acid of the sum of undissociated acetic acid molecules (CH 3 C CH), dissociated acetate ions (CH 3 COO), and undissociated acetate. Means the concentration converted to This is because acetic acid taken from the mouth is either a low pH acetic acid solution, a neutralized form of acetate (eg, sodium acetate), or dissociated acetate.
  • the pH of the intestinal tract after the stomach and small intestine where these absorptions take place is not significantly affected by the composition of the composition, and is kept almost constant at each site, so that the pH in the mouth This is because the presence state of acetic acid molecules in the composition does not affect the absorption of acetic acid in the body. Therefore, the composition of the present invention may contain at least one selected from acetic acid, acetate ion, and acetic acid salt (hereinafter, sometimes referred to as “acetic acids”).
  • acetic acids for example, a carboxylic acid analyzer (EYELA carboxylic acid analyzer S-30000) manufactured by Tokyo Rika Kikai Co., Ltd. can be used.
  • the acetic acid contained in the solution can be separated regardless of dissociation or non-dissociation by using this device that detects various organic acids by using a principle of separating organic acids by a column and reacting specifically with carboxyl groups. Can be determined.
  • composition of the present invention comprises at least one selected from acetic acid, acetate ion and acetate. These can also be obtained by mixing one type with an appropriate amount of another raw material (food raw material, pharmaceutical raw material).
  • the form of the composition of the present invention is not particularly limited.
  • food for specified health use (health food), vinegar, sushi, marinade, beverage, medicine (tablet, capsule, powder, granule, fine granule, drink) ) And the like.
  • the method of adding acetic acid is not particularly limited, and a general method may be used.However, when acetic acid is used not in the form of a salt but in the form of a low pH solution such as synthetic acetic acid or brewed vinegar. Is a problem of ease of drinking and eating, so attention needs to be paid to the sourness of low pH. Specifically, when a low pH solution is ingested, problems such as poor throat and choking occur. When it is desired to increase the concentration, it is possible to adopt an aspect such as use of acetate and conversion to Z or force.
  • the concentration of acetic acid in the composition must be at least 6 mM for liquids, and 0.36 g of acetic acid per 100 g of composition for solids. is there. At lower concentrations, it is necessary to eat very large amounts of food and drink large amounts of drinks.
  • the daily intake is calculated and set based on the assumption that the daily intake is about 150 g for food and the same for drinks, about 1 L.
  • the required daily intake is about 0.5 g to 5 g as acetic acid (molecule).
  • acetic acid molecule
  • vinegar or sushi it is possible to obtain the required amount of effective acetic acid molecules by ingesting one or more servings per day. It is also possible to ingest the required amount of effective acetic acid molecules by consuming about 1 L of a drink containing vinegar, such as apple cider vinegar, from 50 m 1 power per day.
  • vinegar such as apple cider vinegar
  • it is possible to consume more than 5 g of acetic acid (molecule) it is not very preferable to consume more than 5 g, considering the taste as food and the ease of eating and drinking. Absent. If acetic acid is used at an excessively high concentration and is not neutralized, it must be taken in consideration of gastrointestinal disorders such as the stomach and intestines.
  • the effect of acetic acid can be expected to lower blood pressure by long-term oral ingestion of about 0.5 g to 5 g per day.
  • long-term oral intake means that the blood pressure of animals became statistically significantly lower than that of the control 3 weeks after switching to the test diet, as determined by animal experiments.
  • composition of the present invention is useful for treating hypertension, in particular, essential hypertension, in which the underlying disease is unclear and accounts for 90% of the disease, and cerebrovascular disease, heart disease, and other vascular lesions caused by it. It is effective for prevention.
  • FIG. 1 is a graph showing acetic acid concentrations in the hepatic portal vein in the control group and the acetic acid group (intake of 10, 30, and 60 minutes).
  • FIG. 2 is a diagram showing the acetic acid concentration in the abdominal artery in the control group and the acetic acid group (10, 30, and 60 minutes after ingestion).
  • FIG. 3 shows the acetic acid concentration in the vena cava in the control group and the acetic acid group (10, 30, and 60 minutes after ingestion).
  • FIG. 4 is a diagram showing changes in body weight in the control group and the acetic acid group.
  • FIG. 5 is a graph showing changes in food consumption in the control group and the acetic acid group.
  • FIG. 6 is a graph showing changes in water consumption in the control group and the acetic acid group.
  • FIG. 7 is a graph showing changes in blood pressure in the control group and the acetic acid group.
  • FIG. 8 is a graph showing changes in heart rate in the control group and the acetic acid group.
  • Figure 9 shows the control group and the acetic acid group (0.36%, 0.72%, 1.5%, 3%,
  • test substances 150 ml each of an aqueous solution prepared by diluting distilled water or a reagent, acetic acid (special grade), with distilled water to give 6% (W / W) was prepared, and these were used as samples.
  • test animal As a test animal, 5 animals (each body weight of about 2 O k) were used for each sample administration group. It was used. The test animals were fasted and fasted the night before the test. Sedatives were administered on the day of the study. After confirming the sedation, oral administration was performed intragastrically.
  • the animals were sacrificed 10 minutes after administration in the case of water and 10 minutes, 30 minutes and 60 minutes after administration in the case of acetic acid aqueous solution.
  • Blood was collected from the hepatic portal vein, the abdominal artery, and the posterior vena cava, and the acetic acid concentration in the serum was measured by gas chromatography.
  • the acetic acid concentration in the serum was as follows.
  • liver portal vein shown in Figure 1.
  • the group with 10 minutes of acetic acid intake showed significantly higher values than the other three groups. (There is a significant difference by ANOV A test; p ⁇ 0.05)
  • the portal vein showed a relatively high acetic acid concentration after 10 minutes, but the acetic acid concentration in the portal vein decreased rapidly with time. In the arteries, as in the portal vein, it reached its maximum value 10 minutes after ingestion, but returned to normal levels 30 minutes later. Due to the rapid uptake and utilization of acetic acid in the periphery, no substantial increase in acetic acid concentration in the vena cava was observed despite acetic acid intake. The highest acetic acid concentration was found in the portal vein at 10 minutes after acetic acid intake, at about 0.8 mM, which was diluted to 1/125 of the administered concentration. Means Thus, acetic acid metabolism is fast, and 30 minutes after ingestion, it is almost the same as fasting. It is clear that it has returned to a level that is inevitable.
  • Dilute acetic acid (special grade) with distilled water to 5% (WXV) and add 3% to powdered feed (test food) and powdered feed without any control (control). These were used as samples.
  • the starting day of administration of the test meal was set to 1 day, and was 8 weeks.
  • test animals had a 5 day pre-breeding period.
  • the blood pressure was measured by a Tailcafff method using a blood pressure measuring device. Heart rate was measured using the pulse of blood pressure as a trigger. The measurement was performed five times, and the average value was calculated.
  • control group weighed 102.5 g on average, while the test group weighed 101.8 g on average, and was not statistically significant. As shown in FIG. 4, there was no significant difference in body weight after 8 weeks between the control group and the test meal group (p> 0.05 by t-test).
  • the heart rate also showed a behavior similar to blood pressure (Fig. 8), but no significant difference was observed at any time from the control group.
  • Example 1 Except for the SHR strain, the type of feed, and the amount of acetic acid added to the feed, the experimental method and conditions were almost the same as in Example 1.
  • the animals used were SHRZHos rats (SPF), 4 weeks old, and each group consisted of 6 animals.
  • Fig. 9 When blood pressure was measured continuously for up to 8 weeks (Fig. 9), there was no significant difference in the 0.36% addition system from the control group at any time. Significantly lower than the control group after 5 weeks in the 0.72% supplemented system, from the 4th week after 1.5% supplemented system, and from the 3rd week after 3-9% supplemented system. (ANOVA test performed, p ⁇ 0.05 indicating significant difference). Therefore, to suppress the rise in blood pressure, the feed should contain at least 0.72% of a 5% acetic acid solution, that is, at least 0.36 g of acetic acid (molecule) per 100 g of feed. Turned out to be necessary.
  • the blood pressure was significantly lower than in the control group at the third week after starting to eat the acetic acid-containing diet, and there was no significant difference until the second week. This indicates that acetic acid must be taken continuously for at least three weeks, with little effect within two weeks.
  • a beverage was produced with the following composition. That is, 5 g of acetic acid (food additive) and 0.2 g of sucralose (food additive) were added to water to make 1 L, mixed and dissolved to prepare a beverage. The acetic acid molecule concentration of this beverage was 83 mM.
  • the beverage is a refreshing drink having a moderate sour taste and excellent in drinkability. Due to the effect of acetic acid molecules, about 100 ml to 1 L per day (0.5 g to 5 g of acetic acid) is used. It is thought that hypertension can be prevented by drinking for a long period of 3 weeks or more.
  • acetic acid concentration in the drink was preferably 30 g or less per 1,000 g.
  • Acetic acid-containing foods (4 servings) were manufactured with the following composition. That is, it was prepared by mixing well 12 green aspira, 2 bacon, 2 g of bonito, 30 ml of soy sauce, 2.3 g of acetic acid (food additive), and 45 ml of tap water. The concentration of acetic acid molecules in the liquid part of this food was about 500 mM (containing about 30 g of acetic acid molecules per liter of liquid).
  • the food is a refreshing vinegar that has a moderate sourness and has a refreshing sensation.
  • Efficacy of acetic acid molecules makes it possible to eat one serving per day and one serving at each meal, that is, about three servings per day (0.58 g to l. Long-term eating (73 g of acetic acid molecule) is thought to reduce blood pressure elevation, thereby preventing hypertension.
  • An acetic acid-containing food was produced according to the following composition and procedure.
  • the ingredients are as follows: 3 rice, 3 water, 3 sweet salted salmon, 4 fresh shiitake mushrooms (shredded), 1 shimeji mushroom, 3 pieces of kinshi egg, 3 green broths (shredded), mixed seasoning Prepare A (2 tablespoons of liquor, 2 tablespoons of water, a mixture of 1 pinch of salt), and seasoning B (mixture of 4 tablespoons of rice vinegar (4.5% acetic acid), 5 tablespoons of sugar and 2 tablespoons of salt) I do.
  • the food is a sushi having a moderate sourness and excellent taste, containing about 2.7 g of acetic acid molecule per the food, and having an amount of about 14 to LZ3 of the finished food per day.
  • Eating 68 g to 0.9 g of acetic acid molecules once to three times (total of 0.68 g to 2.7 g of acetic acid molecules) suppresses the increase in blood pressure, thereby reducing hypertension. It can be prevented.
  • a beverage was produced with the following composition. That is, 5 g of acetic acid (food additive) and 0.5 g of stevioside (food additive) were added to water to make 1 L, mixed and dissolved to prepare a beverage.
  • the acetic acid molecule concentration of this beverage was 83 mM.
  • the beverage is a refreshing drink having a moderate sour taste and excellent in drinkability. Due to the effect of acetic acid molecules, about 100 ml to 1 L per day (0. (5 g to 5 g of acetic acid molecule) It is considered that long-term drinking suppresses an increase in blood pressure and, as a result, can prevent hypertension.
  • a beverage was produced with the following composition. That is, two teaspoons of apple cider vinegar (acetic acid concentration 5%), two teaspoons of honey, and 150 ml of cold water were mixed and dissolved to prepare a beverage.
  • the acetic acid molecule concentration of this beverage was about 120 mM.
  • the drink is a refreshing drink having a moderate sourness and excellent in drinkability. Due to the effect of acetic acid molecules, it is about 100 ml to 700 ml per day (0.7 g to 5 g of acetic acid molecules). It is thought that the long-term consumption of is suppressed the rise of blood pressure, and as a result, can prevent hypertension.
  • Acetic acid was adsorbed on dextrin and dried to prepare a powder containing acetic acid at a content of 15% (W / W). 6 parts by weight of this powder was added to 94 parts by weight of a powder consisting of sugar, skim milk powder and lactose, and mixed well to obtain a powder.
  • the powder has a moderate sourness, and if 100 g (0.9 g of acetic acid molecule) is orally ingested per day for a long period of time, a rise in blood pressure is suppressed, and as a result, high blood pressure can be prevented. Conceivable.
  • Tablets were prepared containing 1.25 g of sodium acetate per 100 g of tablet (25 mg per tablet). By taking 70 g of these tablets per day (35 tablets, 0.63 g of acetic acid molecule) for a long period of time, it is considered that the increase in blood pressure is suppressed, and as a result, hypertension can be prevented.
  • Example 10 Effect test of acetic acid in hypertensive patients
  • Test beverage consisted of a beverage containing 1.5 g of acetic acid, a beverage containing 75 g of acetic acid and lg lactic acid, and a placebo beverage containing 2 g of lactic acid instead of acetic acid (in each case, 100 ml / bottle). ) was used. Table 1 shows the composition of each test beverage.
  • the three beverages were almost the same in appearance, sweetness, salty taste, etc., except for slightly different acidity, and it was confirmed that they could not be distinguished in appearance.
  • acetic acid vinegar with a mild acidity and a favorable flavor ("Apple vinegar” manufactured by Mizkan Co., Ltd .: acetic acid concentration 5% (W / V)) was used. Lactic acid used was fermented lactic acid.
  • Subjects were those with mild or moderate hypertension who had sustained systolic blood pressure of 140-180 nrniHg or diastolic blood pressure of 90-105 nmiHg for 3 months before the start of the study. And however, those with secondary hypertension, those who were urgently required to administer antihypertensive drugs by a physician, those with alcoholism, severe anemia, and those with severe illness were excluded. . In addition, we excluded those who regularly took any oral medication and those who were taking regular supplements that could affect blood pressure.
  • the study employed a double-blind study and conducted a parallel comparison between three groups of two acetic acid-containing beverages with different acetic acid contents and a placebo beverage.
  • the test period consisted of a 3-week pre-observation (non-consumption) period, an 8-week intake period, and a 4-week observation (non-consumption) period for a total of 15 weeks.
  • test drink should be taken once daily, in the morning, Ingest 1 bottle (100 ml) of Sepo beverage (100 ml) or 0.75 g of acetic acid, or 100 ml of acetic acid-containing beverage containing 1.5 g of acetic acid I decided that. Subjects were instructed to avoid binge eating during the study and were instructed not to make any other changes to their daily life.
  • the blood test was performed on a hunger-free condition after 9 o'clock the night before, with blood sampling being completed between 8:30 am and 11 am, and a clinical test company was asked to take measurements. Blood was collected in a sitting position after maintaining a resting state for at least 10 minutes to avoid extrinsic effects on serum protein components, serum lipid levels, and renin activity.
  • Urinalysis was performed using a test strip method to test for sugar, protein, peroprinogen, and occult blood.
  • Blood pressure and pulse measurement were from 8:30 am to 11:30 am, and the test time was fixed for each subject. On the day of the examination, visit the hospital without any water or test drinks, and after resting for at least 10 minutes after the visit, sit down and take off your shoes, and measure the left arm and elbow for 1 minute. The measurement was performed three times at intervals of. As the measured blood pressure, the blood pressure and pulse rate when the systolic blood pressure showed the median value were defined as the blood pressure and pulse rate on that day. Blood pressure measurement during the study period, before the pre-observation period, immediately before the intake period, 2, 4, 6, and 8 weeks after the start of the intake, and 2 and 4 weeks after the end of the intake A total of 8 times were performed during the interim period (post observation period).
  • Body weight was measured at the doctor's consultation and interview. Weight measurements were made to minimize the effects of clothing.
  • AN0VA two-way analysis of variance
  • Table 2 shows the changes in blood pressure and pulse during the test period.
  • systolic blood pressure a two-way analysis of variance showed that the systolic blood pressure during the intake period fluctuated differently among the three groups (P ⁇ 0.05).
  • the high-dose group 1.5 g / day acetic acid intake group
  • the 75 g / day acetic acid intake group 75 g / day acetic acid intake group
  • DBP di as to lic blood pressure
  • the composition of the present invention which provides a safe and secure composition for suppressing a rise in blood pressure, can suppress a rise in blood pressure.
  • it is effective in suppressing blood pressure rise for those who have a borderline blood pressure or who are destined for essential hypertension.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions permettant de réguler une augmentation de la pression sanguine et présentant une sécurité élevée sans effets secondaires. L'invention concerne notamment des compositions alimentaires ou médicinales permettant de prévenir l'hypertension, une augmentation de la pression sanguine étant régulée au moyen d'une prise orale sur une longue période. Lesdites compositions son caractérisées en ce qu elles contiennent au moins un élément sélectionné dans le groupe constitué par l'acide acétique, un ion acétate et des sels d'acide acétiques.
PCT/JP2002/001967 2000-12-26 2002-03-04 Compositions permettant de prevenir l'hypertension Ceased WO2003074039A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001298211A JP2002255801A (ja) 2000-12-26 2001-09-27 高血圧予防用組成物
PCT/JP2002/001967 WO2003074039A1 (fr) 2001-09-27 2002-03-04 Compositions permettant de prevenir l'hypertension
US10/506,325 US20050256195A1 (en) 2000-12-26 2002-03-04 Composition for preventing hypertension
CA002477900A CA2477900A1 (fr) 2002-03-04 2002-03-04 Composition permettant de prevenir l'hypertension
KR10-2004-7013025A KR20040094717A (ko) 2002-03-04 2002-03-04 고혈압 예방용 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001298211A JP2002255801A (ja) 2000-12-26 2001-09-27 高血圧予防用組成物
PCT/JP2002/001967 WO2003074039A1 (fr) 2001-09-27 2002-03-04 Compositions permettant de prevenir l'hypertension

Publications (1)

Publication Number Publication Date
WO2003074039A1 true WO2003074039A1 (fr) 2003-09-12

Family

ID=29713501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001967 Ceased WO2003074039A1 (fr) 2000-12-26 2002-03-04 Compositions permettant de prevenir l'hypertension

Country Status (1)

Country Link
WO (1) WO2003074039A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058312B2 (en) 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63198953A (ja) * 1987-02-16 1988-08-17 Nakano Vinegar Co Ltd 血糖低下作用を有する食品
JPH0690733A (ja) * 1992-09-14 1994-04-05 Gun Ei Chem Ind Co Ltd 食 酢
JPH1028567A (ja) * 1996-07-17 1998-02-03 Kazumasa Ito 醸造酢を主成分とする飲料食品

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63198953A (ja) * 1987-02-16 1988-08-17 Nakano Vinegar Co Ltd 血糖低下作用を有する食品
JPH0690733A (ja) * 1992-09-14 1994-04-05 Gun Ei Chem Ind Co Ltd 食 酢
JPH1028567A (ja) * 1996-07-17 1998-02-03 Kazumasa Ito 醸造酢を主成分とする飲料食品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONDO S. et al., "Antihypertensive Effects of Acetic Acid and Vinegar on Spontaneously Hypertensive Rats, Bioscience", Biotechnology, and Biochemistry, 2001, Vol. 65, No. 12, pages 2690 - 2694 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058312B2 (en) 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US8541474B2 (en) 2007-01-29 2013-09-24 Hanall Biopharma Co., Ltd. N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same

Similar Documents

Publication Publication Date Title
Lagua et al. Nutrition and diet therapy reference dictionary
KR20040044455A (ko) 혈당치 콘트롤용 영양 조성물
JP2011098896A (ja) 尿酸値低下用組成物
JP3906716B2 (ja) 耐糖能異常用薬剤
JPH01294631A (ja) 糖尿性疾患治療予防剤及び飲食、し好物
JP2021065226A (ja) 認知機能速度改善用の組成物
Nakamura et al. Effects of the liquid yogurts containing “lactotripeptide (VPP, IPP)” on high-normal blood pressure
JP2004520341A (ja) 血圧低下効果を有する機能製品中のベタインの使用
EP3302453B1 (fr) Compositions comprenant du cinnamaldéhyde et du zinc et procédés d'utilisation de ces compositions
JP2002255801A (ja) 高血圧予防用組成物
JP6977053B2 (ja) ギ酸またはその薬学的に許容可能な塩を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物
WO2002076455A1 (fr) Agents de regulation autonome et poissons et aliments dietetiques
JP6044667B2 (ja) 耐糖能異常用医薬組成物及び飲食品
WO2003074039A1 (fr) Compositions permettant de prevenir l'hypertension
EP2136798B1 (fr) Composition utile pour la prévention des diabètes de type 2 et ses complications pour les patients pré-diabétiques résistant à l'insuline
JP4163801B2 (ja) アルコール代謝促進作用物
US20050256195A1 (en) Composition for preventing hypertension
JP4435882B2 (ja) アルコール吸収抑制組成物
KR20040094717A (ko) 고혈압 예방용 조성물
WO2020222302A1 (fr) Nouvelle composition pharmaceutique
EP4137206A1 (fr) Agent pour améliorer la qualité du sommeil
US20080124449A1 (en) Food for Preventing Life Style-Related Diseases
JP5076327B2 (ja) 分岐鎖アミノ酸の心不全適応
HK40083684A (en) Agent for improving quality of sleep
JP4559380B2 (ja) 肝疾患治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA KR US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020047013025

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2477900

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10506325

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020047013025

Country of ref document: KR